pharma · Chronic Spontaneous Urticaria · Asthma
Novartis India
Novartis Pharmaceuticals
Novartis Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Spontaneous Urticaria, Asthma, Systemic Lupus Erythematosus, Breast Cancer, Multiple Sclerosis. NovaP
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Mumbai, IN
- Founded
- 1996
- Employees
- 2,240
- Programs
- 341
- Drugs
- 317
- Patents
- 0
CJDQ443A12101
Phase 2 · small molecule · Advance solid tumors harboring the KRAS G12C mutation
CJDQ443A12101 for Advance solid tumors harboring the KRAS G12C mutation is a Phase 2 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code CJDQ443A12101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Advance solid tumors harboring the KRAS G12C mutation
- Status
- active
- Trials
- 1